Evaluating significance of Geriatric Assessments, a multicenter Prospective Observational Study in real World diffuse large B-cell lymphoma patients of Elderly.

Evaluating significance of Geriatric Assessments, a multicenter Prospective Observational Study in real World diffuse large B-cell lymphoma patients of Elderly. - G-POWER

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054212

Enrollment

500

Registered

2024-04-21

Start date

2024-04-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse large B-cell lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients newly diagnosed with CD20 positive DLBCL as per the WHO classification (Revised 4th edition, 2017), untreated, and including those with transformed cases (pre-treatment steroid administration is permissible). The specific histological diagnoses considered in this study are: DLBCL (NOS): Diffuse large B-cell lymphoma, not otherwise specified THRLBCL: T-cell/histiocyte-rich large B-cell lymphoma EBV DLBCL (NOS): EBV-positive diffuse large B-cell lymphoma, not otherwise specified ALK(+) LBCL: ALK-positive large B-cell lymphoma HHV8 DLBCL (NOS): HHV8-positive diffuse large B-cell lymphoma, not otherwise specified HGBL (MYC, BCL2/6): High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements HGBL (NOS): High-grade B-cell lymphoma, not otherwise specified (2) Patients diagnosed at the age of 70 years or older. (3) Patients scheduled to be treated with one of the following therapies: Pola-R-CHP, R-CHOP, R-THP-COP, R-EPOCH (dosage determined by the facility and attending physician). (4) Patients without CNS involvement. (5) Patients from whom consent has been obtained in writing, either by the patients themselves or by their legal representatives. (6) Asian patients.

Exclusion criteria

Exclusion criteria: (1) Patients who are judged by the principal investigator or sub-investigator to be inappropriate to participate in this study.

Design outcomes

Primary

Measure	Time frame
Evaluation of physical and physiological function decline in elderly DLBCL patients using a geriatric assessment and construction of a frailty scale.	—

Secondary

Measure	Time frame
Understanding the treatment outcomes in elderly DLBCL patients. Evaluation of initial treatment conditions using the newly constructed frailty scale derived from geriatric assessments. Assessment of the relationship between the newly constructed frailty scale from geriatric assessments and clinical outcomes. Evaluation of the relationship between treatment intensity, clinical outcomes, and the newly constructed frailty scale from geriatric assessments. Evaluation of the efficacy and safety of initial treatment regimens in elderly DLBCL patients. Understanding geriatric assessments.	—

Measure

Time frame

Understanding the treatment outcomes in elderly DLBCL patients. Evaluation of initial treatment conditions using the newly constructed frailty scale derived from geriatric assessments. Assessment of the relationship between the newly constructed frailty scale from geriatric assessments and clinical outcomes. Evaluation of the relationship between treatment intensity, clinical outcomes, and the newly constructed frailty scale from geriatric assessments. Evaluation of the efficacy and safety of initial treatment regimens in elderly DLBCL patients. Understanding geriatric assessments.

—

Countries

Japan

Contacts

Public ContactNobuhiko Nakamura

Gifu University Hospital Department of Hematology and Infectious Diseases

nakamura.nobuhiko.s1@f.gifu-u.ac.jp058-230-6000

Outcome results